ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer скачать в хорошем качестве

ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, comments on the efficacy and completion rates of the randomized Phase III ANZUP 1301 trial (NCT02948543) comparing BCG plus mitomycin to BCG alone in high-risk, non–muscle-invasive bladder cancer. Prof. Hayne notes that the BCG plus mitomycin regimen showed similar efficacy and adverse events to BCG alone, but with improved completion rates and reduced BCG doses required. This regimen, particularly in higher-risk patients, may offer a promising alternative to BCG alone, especially in light of the global BCG shortage, which could be alleviated by widespread adoption of the BCG plus mitomycin regimen. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.